Century Therapeutics Inc (NASDAQ: IPSC) on Monday, plunged -3.31% from the previous trading day, before settling in for the closing price of $0.57. Within the past 52 weeks, IPSC’s price has moved between $0.34 and $1.83.
During the last 5-year period, the sales growth of Healthcare Sector giant was 18.46%. The company achieved an average annual earnings per share of 93.01%. With a float of $40.70 million, this company’s outstanding shares have now reached $86.32 million.
Let’s determine the extent of company efficiency that accounts for 150 employees.
Century Therapeutics Inc (IPSC) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Century Therapeutics Inc is 52.88%, while institutional ownership is 23.59%. The most recent insider transaction that took place on Sep 08 ’25, was worth 132. In this transaction SVP Finance & Operations of this company sold 263 shares at a rate of $0.50, taking the stock ownership to the 405,423 shares. Before that another transaction happened on Sep 08 ’25, when Company’s President and CEO sold 488 for $0.50, making the entire transaction worth $244. This insider now owns 3,268,909 shares in total.
Century Therapeutics Inc (IPSC) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.37 earnings per share (EPS) for the period topping the consensus outlook (set at -0.45) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 93.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.74% during the next five years compared to 18.46% growth over the previous five years of trading.
Century Therapeutics Inc (NASDAQ: IPSC) Trading Performance Indicators
Century Therapeutics Inc (IPSC) is currently performing well based on its current performance indicators. A quick ratio of 10.72 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.24 in one year’s time.
